Rigel Pharma (RIGL) Misses Q4 EPS by 1c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Rigel Pharma (RIGL) Misses Q4 EPS by 1c, Revenues Beat

Rigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update

February 28, 2019 4:01 PM EST

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a business update.

Recent Highlights

Fourth quarter 2018 total revenues were $37.9 million; including $30.6 million in collaboration revenues and $7.3 million in net product sales of TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment Full year 2018 total revenues were $44.5 million, including $13.9 million in net... More